RenovoRx Highlights Key Leadership Promotions

RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today highlighted the recent key leadership promotions of Leesa Gentry to Chief Clinical Officer and Ronald B. Kocak, CPA to Principal Accounting Officer.

Shaun Bagai, Chief Executive Officer of RenovoRx, commented, “We are delighted to promote Leesa and Ron to their new leadership roles, which reflects our commitment to assembling a dynamic team poised to continue to lead a successful clinical pathway for our proprietary therapy platform. We have streamlined our team, focusing our efforts on strategic initiatives to drive growth and innovation. On behalf of our Board of Directors, I extend our gratitude to Leesa and Ron on their hard work and dedication to date and congratulate them on their well-deserved promotions.”

Ms. Gentry has served as Senior Vice President of Clinical Operations at RenovoRx since April 2023. In her new role as Chief Clinical Officer, she will oversee clinical and regulatory operations ensuring the highest standards for safety and quality are met across RenovoRx clinical studies. Ms. Gentry will continue to implement her breadth of experience as the Company drives towards a second interim analysis for the Phase III TIGeR-PaC study evaluating RenovoRx’s lead product candidate, RenovoGem^TM for the treatment of Locally Advanced Pancreatic Cancer (LAPC), which is expected by late 2024.

Since joining RenovoRx, Ms. Gentry has demonstrated exemplary leadership and commitment to advancing the Company’s clinical pipeline. In 2023, Ms. Gentry helped to achieve the first interim analysis in the TIGeR-PaC with the Data Monitoring Committee recommending a continuation of the study. The TIGeR-PaC study’s primary endpoint is a 6-month Overall Survival benefit with secondary endpoints including reduced side effects versus standard of care. Under her guidance, the Company’s clinical strategy to date has yielded positive results that contribute to the Company’s commitment to improve patients’ lives and lifespans by delivering therapies that have the potential to revolutionize the current paradigm of cancer care.